L26/P-648 Outcomes following PGT-A: an age-stratified emulated trial analysis using 110,403 UK IVF cycles
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von Y. Beebeejaun und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does use of PGT-A in IVF cycles associate with improved clinical pregnancy and live birth rates, and do associations vary by female age? Summary answer Use of PGT-A was associated with higher clinical pregnancy and live birth rates, with stronger associations observed with advancing female age. What is known already Embryo selection in IVF is traditionally based on morphology, yet many morphologically high-quality embryos fail to implant. PGT-A, most commonly performed using next-generation sequencing, has been proposed to improve embryo selection by identifying euploid embryos. However, evidence for clinical benefit remains inconsistent. Conventional observational studies are vulnerable to selection and immortal time bias, while randomised trials are limited by sample size and generalisability. Emulated trial frameworks using large registries may provide complementary real-world evidence. Study design, size, duration A population-based emulated target trial was conducted using anonymised cycle-level data from the UK Human Fertilisation and Embryology Authority registry. A total of 110,403 autologous IVF/ICSI cycles meeting eligibility criteria were included. Cycles were analysed across the study period covered by the registry. Donor cycles, PGT-M cycles, and cycles with two or more embryos transferred were excluded. Participants/materials, setting, methods Eligible participants included women undergoing autologous IVF/ICSI cycles. Exclusions were donor oocyte cycles, PGT-M cycles, and cycles with two or more embryos transferred. Cycles without embryo transfer were retained and contributed zero events, consistent with an intention-to-treat estimand. Baseline confounding was addressed using propensity score–based overlap weighting to improve balance in the region of clinical equipoise; weighted Poisson regression estimated risk ratios in age-stratified analyses performed in Stata. Main results and the role of chance Overall, clinical pregnancy rates were higher in the PGT-A group (RR 1.64; 95% CI 1.55–1.73), as were live birth rates (RR 1.71; 95% CI 1.61–1.83), with a modest reduction in miscarriage risk (RR 0.83; 95% CI 0.70–0.99). Age-stratified analyses demonstrated a clear gradient in associations according to female age. In women aged <35 years, PGT-A use was associated with moderate increases in clinical pregnancy (RR 1.38; 95% CI 1.22–1.56) and live birth rates (RR 1.43; 95% CI 1.24–1.64), with no statistically significant difference in miscarriage rates (RR 0.83; 95% CI 0.52–1.32). In women aged ≥35 years, larger relative differences were observed, with higher clinical pregnancy (RR 1.99; 95% CI 1.86–2.13) and live birth rates (RR 2.19; 95% CI 2.02–2.37), alongside lower miscarriage rates (RR 0.69; 95% CI 0.56–0.85). Associations strengthened with advancing age, with progressively larger relative differences in live birth rates observed in women aged ≥38 and ≥40 years. Associations strengthened with advancing age, with progressively larger relative differences in live birth rates observed in women aged ≥38 and ≥40 years (RR 3.18; 95% CI 2.89–3.51; RR 4.70; 95% CI 4.11–5.36) with consistently lower miscarriage risks in these older age groups. Limitations, reasons for caution Residual confounding cannot be excluded. The HFEA registry has limited ability to fully match treatment groups on key prognostic factors, including prior live birth history and underlying embryo cohort quality. Limited overlap between PGT-A and non-PGT-A cycles restricts inference to the overlap population. Embryology- and laboratory-level variables are unavailable. Wider implications of the findings These findings suggest age-dependent differences in outcomes associated with PGT-A use in routine IVF practice, particularly among older women. Limitations in covariate overlap and registry granularity highlight the need for cautious interpretation and reinforce the importance of complementary randomised trials and improved registry data to inform patient counselling. Trial registration number No
Zitieren
APA
Beebeejaun, Y., Copeland, T., & Sunkara, S. (2026). L26/P-648 Outcomes following PGT-A: an age-stratified emulated trial analysis using 110,403 UK IVF cycles. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.978
Vancouver
Beebeejaun Y, Copeland T, Sunkara S. L26/P-648 Outcomes following PGT-A: an age-stratified emulated trial analysis using 110,403 UK IVF cycles. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.978
BibTeX
@article{Beebeejaun2026,
author = {Beebeejaun, Y. and Copeland, T. and Sunkara, S.},
title = {L26/P-648 Outcomes following PGT-A: an age-stratified emulated trial analysis using 110,403 UK IVF cycles},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.978}
}
EUVIMED